Comparative efficacy and tolerability of 5-Loxin and AflapinAgainst osteoarthritis of the knee: a double blind, randomized, placebo controlled clinical study - Wikidata - awgldk - TriplyDB

Comparative efficacy and tolerability of 5-Loxin and AflapinAgainst osteoarthritis of the knee: a double blind, randomized, placebo controlled clinical study

Comparative efficacy and tolerability of 5-Loxin and AflapinAgainst osteoarthritis of the knee: a double blind, randomized, placebo controlled clinical study

http://www.wikidata.org/entity/Q34280379

about

Oral herbal therapies for treating osteoarthritis Benefits of antioxidant supplements for knee osteoarthritis: rationale and reality Construction and verification of the targeted uPA-shRNA lentiviral vector and evaluation of the transfection and silencing rate.Effect of a Herbal-Leucine mix on the IL-1β-induced cartilage degradation and inflammatory gene expression in human chondrocytes.Current nutraceuticals in the management of osteoarthritis: a review Ayurvedic interventions for osteoarthritis: a systematic review and meta-analysis.A double blind, randomized, placebo controlled clinical study evaluates the early efficacy of aflapin in subjects with osteoarthritis of knee.Comparative effectiveness of a complex Ayurvedic treatment and conventional standard care in osteoarthritis of the knee--study protocol for a randomized controlled trial.Phytomedicine in Joint Disorders.Plant food supplements with anti-inflammatory properties: a systematic review (II).Medical Plant Extracts for Treating Knee Osteoarthritis: a Snapshot of Recent Clinical Trials and Their Biological Background.Boswellic Acids and Their Role in Chronic Inflammatory Diseases.Management strategies for Janu Sandhigata Vata vis-a-vis osteoartheritis of knee: A narrative review.Methylsulfonylmethane and boswellic acids versus glucosamine sulfate in the treatment of knee arthritis: Randomized trial.Boswellic acids reduce Th17 differentiation via blockade of IL-1β-mediated IRAK1 signaling.Long-term efficacy of Boswellia serrata in four patients with chronic cluster headache.Efficacy and safety of curcumin and its combination with boswellic acid in osteoarthritis: a comparative, randomized, double-blind, placebo-controlled study.Clinical comparison of oral administration and viscosupplementation of hyaluronic acid (HA) in early knee osteoarthritis.Management strategies for knee osteoarthritis: Aflapin® (Boswellia serrata extract).Wild Plant-Based Functional Foods, Drugs, and Nutraceuticals

P2860

Q24194586-A76B2C6B-D7DB-4259-8C19-BC123406A1FE Q28071711-5352D742-79CB-49B7-BD73-084F2AD23608 Q33837424-D0BAF98E-C4A9-4B47-AB7B-860E67F01FBD Q33997682-3CF0B885-9C72-48C8-B699-2C8F26936D03 Q34291608-47762A63-E19E-4AA1-8B61-36F2CF0AAE92 Q34430912-B5DD7661-AD92-4361-A1B1-D10727EB1E4E Q35407746-81408813-3131-44DD-BA1F-D6603333FA3D Q36877560-9FD9BBF6-A2FC-4CDB-AA3E-52AE3255DE02 Q37628462-43523A84-C820-463C-9DAF-9B0FC53CC86E Q38079846-DCFD9C7D-9552-4A94-B7FE-A91E899A97D7 Q38545133-F4286750-656D-42B7-A1E5-255C0D7EAE7A Q38965222-60F5EB57-2914-4BD3-AAC6-29D93BAE10D7 Q41226437-D2AB394A-C648-415D-BAE9-D1B90EF5F384 Q43928353-CA1C7EAB-7DDF-45DD-8781-60DE2D349CC7 Q46940257-68F0EF85-8AAB-4564-8273-C33321F3600E Q48234694-221B0A08-5237-46F2-8A2D-0C316DFBB5ED Q49639609-B2305BC8-56CE-4D0B-B7CD-BF4C1C5BF67B Q53988473-D0C53B55-B6A2-4BCB-940D-1407D34FD9AA Q55069575-5EEEB923-9880-4974-9AA8-85468019361A Q57614934-BDAEF1E7-123B-43DE-BDBA-FDB3F7E4B0F8

P2860

Comparative efficacy and tolerability of 5-Loxin and AflapinAgainst osteoarthritis of the knee: a double blind, randomized, placebo controlled clinical study

http://www.wikidata.org/entity/Q34280379

description

2010 nî lūn-bûn

@nan

2010 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի նոյեմբերին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年学术文章

@wuu

2010年学术文章

@zh-cn

2010年学术文章

@zh-hans

2010年学术文章

@zh-my

2010年学术文章

@zh-sg

2010年學術文章

@yue

name

Comparative efficacy and toler ...... cebo controlled clinical study

@ast

Comparative efficacy and toler ...... cebo controlled clinical study

@en

Comparative efficacy and toler ...... cebo controlled clinical study

@nl

type

label

Comparative efficacy and toler ...... cebo controlled clinical study

@ast

Comparative efficacy and toler ...... cebo controlled clinical study

@en

Comparative efficacy and toler ...... cebo controlled clinical study

@nl

prefLabel

Comparative efficacy and toler ...... cebo controlled clinical study

@ast

Comparative efficacy and toler ...... cebo controlled clinical study

@en

Comparative efficacy and toler ...... cebo controlled clinical study

@nl

P1433

Q34280379-8B9FD422-FCC1-4DC5-9CA4-C8ADB168F09B

P1476

Q34280379-522654EC-2CC1-40F4-818A-948FD0DADB5E

P2093

Q34280379-129C4E82-0657-49C5-8A52-E1E37DB27A2A

Q34280379-37012D35-340C-41D9-BA75-52DEFE67CC53

Q34280379-4A316FB1-183F-406C-B2A5-819793CFA5A1

Q34280379-5C8D92B4-6177-4DAE-BECF-FD707EF0C480

Q34280379-5F93E6E9-4755-4B4B-B6A7-BED9FFE693E7

Q34280379-63EA6F0C-FF78-423F-BC0B-0A940EA56344

Q34280379-93E7EE09-1EDB-4E24-A93C-38991834F632

Q34280379-96BDEF54-C746-480C-AA59-56BA21D1F30D

P2860

Q34280379-03B909B7-1433-4568-8242-3DF3B27A29E9

Q34280379-0BD5F6B5-D707-4538-8DFE-44A4EC66A6EE

Q34280379-0EC684E1-BBD9-403A-B17D-289EF469E40B

Q34280379-1AB89A23-A04D-4100-8797-2476EF63B691

Q34280379-22600EB5-5599-4673-89D2-A42C1BBC8329

Q34280379-3885AA60-39A1-4B6F-836C-AF86B41C3D6F

Q34280379-38D7834E-4141-4C15-818D-7A7DEF1AECBD

Q34280379-3F658052-4988-4EC7-BAC0-CF6B95C971B6

Q34280379-43D9E2C4-DEA4-416A-AF92-3A6C01C3FC40

Q34280379-4D8D5C69-2E1E-4D58-BD06-59FDDF62BFB7

P304

Q34280379-68877254-800B-499D-AE15-45839BD5A8A8

P31

Q34280379-E7BAEC29-783F-4A25-BE4D-5D0AE1191948

P356

Q34280379-9604E6A6-E47F-4606-A2CF-AB7CF6F0B709

P407

Q34280379-8D1AC55F-7438-40D9-99BC-C35087F04267

P433

Q34280379-8A720170-BE74-41AC-B27D-E5F6FF5C5064

P478

Q34280379-97C5C2CE-D898-4D09-9694-E2F99BFD5F39

P577

Q34280379-CBD4E08C-EFED-4151-BA23-846C70117CAE

P698

Q34280379-B5CF3FBF-3877-48CE-9013-21A26A4FEDEF

P921

Q34280379-26DB68F6-6CF4-46BD-9267-D34E4E2D77BD

Q34280379-DF5C5898-49A9-4EE5-87E3-844EFDD610CD

P932

Q34280379-BFFBF6B5-59EA-4D0F-8F38-833D922BA268

P356

P1433

International Journal of Medical Sciences

P1476

Comparative efficacy and toler ...... cebo controlled clinical study

@en

P2093

Alluri V Krishnaraju

http://www.w3.org/2001/XMLSchema#string

Amar A Vishal

http://www.w3.org/2001/XMLSchema#string

Artatrana Mishra

http://www.w3.org/2001/XMLSchema#string

Golakoti Trimurtulu

http://www.w3.org/2001/XMLSchema#string

Kadainti V S Sarma

http://www.w3.org/2001/XMLSchema#string

Krishanu Sengupta

http://www.w3.org/2001/XMLSchema#string

Siba P Raychaudhuri

http://www.w3.org/2001/XMLSchema#string

Smriti K Raychaudhuri

http://www.w3.org/2001/XMLSchema#string

P2860

The therapeutic effect of clinical trials: understanding placebo response rates in clinical trials--a secondary analysis.

Understanding NSAIDs: from aspirin to COX-2

Mechanisms underlying the anti-inflammatory actions of boswellic acid derivatives in experimental colitis

Validation study of WOMAC: a health status instrument for measuring clinically important patient relevant outcomes to antirheumatic drug therapy in patients with osteoarthritis of the hip or knee

Mechanisms involved in cartilage proteoglycan catabolism.

Matrix metalloproteinases are involved in C-terminal and interglobular domain processing of cartilage aggrecan in late stage cartilage degradation.

Use of complementary and alternative medicine in Germany - a survey of patients with inflammatory bowel disease.

Osteoarthritis: new insights. Part 1: the disease and its risk factors.

Molecular basis and clinical use of biochemical markers of bone, cartilage, and synovium in joint diseases.

Efficacy and safety of etoricoxib 30 mg and celecoxib 200 mg in the treatment of osteoarthritis in two identically designed, randomized, placebo-controlled, non-inferiority studies.

P304

366-377

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.7150/IJMS.7.366

http://www.w3.org/2001/XMLSchema#string

P407

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

7

http://www.w3.org/2001/XMLSchema#string

P577

2010-11-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

21060724

http://www.w3.org/2001/XMLSchema#string

P921

P932

2974165

http://www.w3.org/2001/XMLSchema#string